[Featured Stock] Esbiomedics, 'Complete Cure Goal' Parkinson's Treatment Value Soars Expected... Clinical Results Next Month

S-Biomedics is showing strong performance. Securities firms' analyses, which expect a re-evaluation as clinical trial results for Parkinson's disease will be announced starting next month, seem to be influencing the stock price.

As of 1:13 PM on the 1st, S-Biomedics is trading at 13,950 KRW, up 19.03% compared to the previous trading day.

Hanyang Securities analyzed that S-Biomedics is undervalued compared to its overwhelming potential. Oh Byung-yong, a researcher at Hanyang Securities, explained, "Parkinson's disease is an incurable disease, and currently, only symptom-relieving drugs exist with no cure available," adding, "The prevalence is rapidly increasing, and the global patient population reaches about 10 million, representing a huge untapped market."

S-Biomedics is developing a new drug called ‘TED-A9’ aimed at fundamentally treating Parkinson's disease. Parkinson's disease occurs due to the death of dopamine-secreting nerve cells in the midbrain. S-Biomedics' new drug is a treatment method that transplants dopamine-secreting nerve cells produced from embryonic stem cells into the patient's midbrain. Theoretically, this method could potentially cure Parkinson's disease. The company has already completed dosing 12 patients in the Phase 1/2a clinical trial of ‘TED-A9’ and is awaiting the results.

Researcher Oh said, "Similar to S-Biomedics, there is a company developing Parkinson's treatments using nerve cells, BlueRock Therapeutics, a subsidiary of Bayer," and explained, "BlueRock was acquired by Bayer in 2019 for a whopping $1 billion (approximately 1.3 trillion KRW)."

He added, "More importantly, at that time, BlueRock had not even started Phase 1 clinical trials for its Parkinson's cell therapy ‘Vemdaneprosel’," and estimated, "BlueRock recently succeeded in Phase 1 trials, so its current valuation is likely much higher."

He continued, "If S-Biomedics' ‘TED-A9’ produces results at a level similar to BlueRock in the Phase 1/2a trial, its value could skyrocket," and said, "Data from the 12-month dosing of low-dose patients is scheduled to be released next month."

Furthermore, he noted, "Despite its overwhelming potential, S-Biomedics' market capitalization is far below that of typical stem cell therapy companies," and added, "The public offering price at the time of listing on May 4 last year was 18,000 KRW."

On this day, S-Biomedics announced that a derivative patent for the development of Parkinson's disease cell therapy, titled ‘Method for isolating dopamine nerve cells and a pharmacological composition for treating Parkinson's disease containing the isolated dopamine nerve cells,’ has been granted registration in China. S-Biomedics has sequentially filed a total of 42 derivative patents for dopamine nerve cell production and application to Parkinson's disease, preparing for the global commercialization of Parkinson's disease cell therapy. The company is strengthening intellectual property rights on key technologies for Parkinson's disease cell therapy.